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Abstract
Background: a-particle emitting isotopes are effective novel tools in cancer therapy, but targeted delivery into tumors is a
prerequisite of their application to avoid toxic side effects. Peritoneal carcinomatosis is a widespread dissemination of
tumors throughout the peritoneal cavity. As peritoneal carcinomatosis is fatal in most cases, novel therapies are needed. F3
is a tumor homing peptide which is internalized into the nucleus of tumor cells upon binding to nucleolin on the cell
surface. Therefore, F3 may be an appropriate carrier for a-particle emitting isotopes facilitating selective tumor therapies.
Principal Findings: A dimer of the vascular tumor homing peptide F3 was chemically coupled to the a-emitter
213Bi (
213Bi-
DTPA-[F3]2). We found
213Bi-DTPA-[F3]2 to accumulate in the nucleus of tumor cells in vitro and in intraperitoneally growing
tumors in vivo. To study the anti-tumor activity of
213Bi-DTPA-[F3]2 we treated mice bearing intraperitoneally growing
xenograft tumors with
213Bi-DTPA-[F3]2. In a tumor prevention study between the days 4–14 after inoculation of tumor cells
661.85 MBq (50 mCi) of
213Bi-DTPA-[F3]2 were injected. In a tumor reduction study between the days 16–26 after
inoculation of tumor cells 661.85 MBq of
213Bi-DTPA-[F3]2 were injected. The survival time of the animals was increased
from 51 to 93.5 days in the prevention study and from 57 days to 78 days in the tumor reduction study. No toxicity of the
treatment was observed. In bio-distribution studies we found
213Bi-DTPA-[F3]2 to accumulate in tumors but only low
activities were found in control organs except for the kidneys, where
213Bi-DTPA-[F3]2 is found due to renal excretion.
Conclusions/Significance: In conclusion we report that
213Bi-DTPA-[F3]2 is a novel tool for the targeted delivery of a-
emitters into the nucleus of tumor cells that effectively controls peritoneal carcinomatosis in preclinical models and may
also be useful in oncology.
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Introduction
A single, high linear energy transfer a-particle can kill a tumor
cell [1]. Therefore, a-particle emitting isotopes may emerge as
effective novel tools in cancer therapy [2]. Due to its high linear
energy transfer, short half life and uncomplicated use
213Bi is
promising for medical applications. To avoid toxic side effects,
targeted delivery of such isotopes into tumors is a prerequisite of
their application in oncology. a-particles kill cells due to induction
of double strand brakes in DNA with a high relative biological
effectiveness. As the range of the particles is only 28–100 mmi n
mammalian tissues, the development of carriers mediating specific
uptake into the nucleus of tumor- or tumor endothelial cells is
important to optimize therapeutic efficacy. Therefore, an ideal
carrier for radionuclide therapy with a-emitters would mediate the
specific uptake of the radionuclide selectively into the nuclei of
tumor cells but not into cells in normal organs. Considering the
short physical half life of
213Bi (45.6 minutes) a quick internali-
zation of the carrier is essential. Tumor-specific monoclonal
antibodies coupled to a-emitters such as
225Ac,
211At,
149Tb or to
213Bi have already been successfully tested by several groups in a
number of clinical and preclinical studies in different tumor
entities including leukemia, glioma, melanoma, lymphoma, breast,
ovarian, neuroblastoma as well as colon-and prostate cancer
[1,3,4,5,6,7]. Peptides may also be used as conjugates for the
targeted delivery of a-emitters into tumors and may be a
promising option for cancer therapy [8]. Although it has been
shown that in animal models
225Ac and
213Bi coupled to
DOTATOC are effective in the treatment of neuroendocrine
tumors, there is only limited experience with alpha particle
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As a first step to develop radionuclide therapies using tumor
homing peptides, it is important to test the binding affinity,
stability and therapeutic efficacy of alpha-emitters coupled to such
peptides in vitro and in vivo.
Peptide libraries displayed on phage can be screened in vivo for
phage particles that home to a specific target [11]. A number of
peptides capable of homing to tumor vasculature were isolated in
this manner [12]. In preclinical models, targeted drug delivery into
tumors has been achieved by conjugation of anti-cancer drugs with
vascular tumor homing peptides [13]. F3 is a 32 amino acid
vascular tumor homing peptide that binds specifically to nucleolin
on the surface of tumor cells [14,15]. In resting cells, nucleolin is
primarily expressed in the nucleus. In contrast, in proliferating
tumor or tumor endothelial cells, nucleolin is cyclically transported
from the nucleus to the cell surface and back by a specific shuttle
mechanism [16]. Therefore, nucleolin is potentially an appropriate
target for selective tumor therapies. Indeed, it has been reported
that F3 is capable of transporting nano-particles or fluorescent
dyes such as FITC into the nuclei of tumor cells and tumor
endothelial cells in vitro and in vivo [17].
Peritoneal carcinomatosis is a widespread dissemination and
implantation of tumors throughout the peritoneal cavity. It is a
frequent and serious complication of intra-abdominal cancers of
the gastrointestinal tract, including carcinomas of the colon,
pancreas and stomach as well as ovarian cancer [18]. Peritoneal
carcinomatosis also occurs in patients with primarily extra-
abdominal tumors such as breast cancer and melanoma. The
majority of patients who are diagnosed with ovarian or pancreatic
cancer already have peritoneal disease at the time of diagnosis.
The vague signs and symptoms associated with peritoneal disease,
such as bloating and early satiety, often delay the diagnosis and the
initiation of treatment, leading to a poor prognosis [19].
Additionally, the lack of an effective treatment strategy leaves
patients at significant risk of recurrence. Therefore, there is an
urgent need to develop more effective tools for the treatment of
peritoneal carcinomatosis. Recent evidence suggests that radionu-
clide therapy may be more beneficial than intra-peritoneal
chemotherapy as treatment for peritoneal carcinomatosis [7].
We generated an F3 dimer coupled to DTPA which chelates
213Bi and tested binding affinity, bio-distribution and anti-tumor
activity of this construct (
213Bi-DTPA-[F3]2) in vitro and in vivo in a
pre-clinical model of peritoneal carcinomatosis. We found that
213Bi-DTPA-[F3]2 binds with high affinity to tumor cells, is
internalized into the nuclei of tumor cells in vitro and is effective in
treatment of peritoneal carcinomatosis.
Materials and Methods
Ethics Statement
All experiments were performed according to the German law
for the protection of animals. The animal experiments were
approved and supervised by the Government of Upper Bavaria
(Regierung von Oberbayern) (record number 55.2-1-54-2531-34-
02 and 55.2-1-54-2531-52-07).
Materials
All materials not further specified were purchased from Sigma,
Deisenhofen, Germany.
Cell Culture
The tumor cell lines MDA-MB-435 (human breast cancer),
MIAPACA (human pancreas carcinoma), OVCAR 3 (ovarian
cancer) and CMT 93 (murine colon cancer) were grown in RPMI
1640 Medium (Biochrom, Berlin, Germany) supplemented with
1% penicillin/streptomycin (10.000 U/10 mg/ml, Biochrom), 1%
gentamycine, 1% L-glutamine (200 mM, Biochrom) und 10%
fetal calf serum (FCS, Biochrom). EMT6-cells were grown in
Waymouth Medium (Gibco) supplemented with 10% FCS und
penicillin/streptomycin (Gibco, 0.1 mg/ml).
Synthesis and labeling of
213Bi-DTPA-[F3]2 and
68Ga-
DTPA-[F3]2
DTPA-[F3]2 was synthesized by GenScript Corporation,
Piscataway, NJ. In this construct the chelator DTPA is coupled
to F3 via its N-terminus.
213Bi was eluted from a
225Ac/
213Bi in-
house-generator provided by the Institute of Transuranium
Elements [20,21] using elution buffer (0.1 M HCl, 0.1 M NaI,
pH 5). For coupling of
213Bi to DTPA-[F3]2 3.3 mg DTPA-[F3]2/
mCi
213Bi were incubated with 100 ml ascorbic acid (40 mg/ml)
und 3 M NH4Ac (pH 5.3) at room temperature for 10 minutes.
Labelling efficacy was tested by ITLC and was .90% in all
experiments. To test stability the constructs were diluted 1:10 with
murine serum, cell culture media or ascites from mice with
peritoneal carcinomatosis and incubated at 37uC for the indicated
times. 1–2 ml of the solution were then submitted to ITLC. The
amount of activity bound to the peptide was then determined
using a c-counter.
Internalization of
213Bi-DTPA-[F3]2 and cell fractionation
in vitro
MDA-MB-435 cells were grown to a density of 1610
7 cells/dish in
10 mm culture dishes. For fractionation of cultured MDA-MB-435
cells after incubation with 1.85 MBq (33 ng/ml)
213Bi-DTPA-[F3]2
for 5, 10, 20, 45, and 90 minutes, cells were washed three times with
ice cold PBS. Culture dishes were placed on ice and 4 ml of ice cold
Nuclei EZ lysis buffer (Nuclei Isolation Kit from Sigma, Deisenhofen,
Germany) were added. Cells were harvested using a bladed cell
scraper. The entire cell lysate from each plate was transferred into a
15 ml centrifuge tube (Falcon), vortexed and set on ice for five
minutes. The nuclei were thenpelletedby centrifugationat 5006gf o r
five minutes, washed by three times with EZ lysis buffer and
resuspended in nuclei EZ storage buffer. The supernatant contains
the cytoplasm and membrane fraction.The integrity of the nuclei was
checked by microscopy. To determine the
213Bi-radioactivity
concentration within the nuclei of tumor cells we determined the
volume and the number of nuclei using a haemocytometer. The
radioactivity present was determined by a using a c-counter and used
for calculation of the radioactivity concentration (MBq/ml).
Cell viability test
1610
6 MDA-MB-435 cells were cultivated in 6 well plates.
After 4 hours for cell adherence, the cells were treated with
different activities of
213Bi-DTPA-[F3]2. Untreated cells and cells
treated with free
213Bi were used as control. After 3 days, cells were
detached with trypsin/EDTA and washed once with PBS. 50 mlo f
the cell solution were mixed with 0.4% trypan blue solution 1:1 for
10 minutes. Total cell count and the rate of unviable cells were
determined using a haematocytometer.
Blocking of
213Bi-DTPA-[F3]2 binding to tumor cells
EMT-6 cells were grown to confluence on glass cover slips. Cells
were washed with PBS and incubated with 40 ng/ml
213Bi-DTPA-
[F3]2 in presence or absence of 400 ng/ml DTPA-[F3]2 for
30 minutes at room temperature. Cover slips were the washed by
three times with PBS and analyzed with a micro-imager
(mImager
TM, Biospace, Germany).
Delivery of Alpha-Emitters
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1610
5 MDA-MB-435, MIAPACA, OvCAR3 and CMT 93
cells were cultivated in 6 well plates for 24 h. Cells were treated
with different activities of
213Bi-DTPA-[F3]2 in cell culture media
(RPMI 1640). After 12 h cells were detached with trypsin, washed
3 times and resuspended in RPMI 1640. 200 ml cell culture
medium with 4610
4 tumor cells were filled into a 15 ml Falcon
tube and mixed with 0.7% low melting agarose and 3 ml 26
RPMI 1640. 1.5 ml of this suspension were added per well of 6-
well plates covered with base agar. Cell culture dishes were then
incubated at 37uC for one week and stained with 0.5 ml 0.005%
Cresyl-violet-solution for the minimum of 1 hour. Colonies were
counted using an inverted microscope (Zeiss, Oberkochen,
Germany).
Tumor model of peritoneal carcinomatosis
To generate intraperitoneal xenograft tumors, 6–8 week old
SCID-mice (Charles River, Sulzfeld, Germany) were injected i.p.
with 1610
7 MDA-MB435 tumor cells. Mice were weighed weekly
and were sacrificed when the mean normal body weigth decreased
,25% or when mice developped tumor side effects like ascites or
reduced general condititon. All experiments were performed
according to the German law for the protection of animals.
Biodistribution of
213Bi-DTPA-[F3]2
213Bi-DTPA-[F3]2 (3.7 MBq) was injected i.p. into SCID-mice
with intra-peritoneal growing tumors in an advanced stage 20 days
after inoculation of tumor cells. After 45 minutes, mice were
sacrificed, the tumors and the organs were surgically removed and
the radioactivity present in each organ (percent of the injected
activity/g=% ID/g), the tumors and the blood was measured
with a c-counter.
Autoradiography and histology
Tumor bearing mice were injected i. p. with 3.7 MBq
213Bi-
DTPA-[F3]2. The tumors and control organs were resected, snap
frozen with liquid nitrogen and cut in 10 mm sections using a
microtome (HM 500 O, Microm, Germany). Sections were then
exposed to a micro-imager (mImager
TM, Biospace, Germany). For
H&E staining 7.5 mm sections were cut, fixed with 37% formalin
and stained with haematoxiline and eosine.
PET-imaging using
68Ga-DTPA-[F3]2
7.4 MBq
68Ga-DTPA-[F3]2 in 100 ml PBS were injected i.p.
into mice bearing intra-peritoneal xenograft tumors 20 days after
inoculation. After 60 minutes mice were anesthetized (3%
isoflurane, O2 4 l/min) and examined with a small animal PET-
scanner (MicroPET Focus 120, Siemens, Germany). Picture
analysis was performed using Osirix
TM software.
Therapy of intraperitoneal xenograft tumors
SCID-mice (Charles River, Sulzfeld, Germany) were injected
i.p. with 1610
7 MDA-MB-435 cells expressing firefly luciferase in
100 ml PBS. In the tumor prevention study groups of 8 mice were
injected every second day with 1.85 MBq
213Bi-DTPA-[F3]2,
1.85 MBq
213Bi-DTPA or 100 ml PBS between day 4 and 14 after
inoculation of the tumor cells. In the tumor reduction study groups
of 8 mice were injected i.p. with 1.85 MBq
213Bi-DTPA-[F3]2 ,
1.85 MBq
213Bi-DTPA or 100 ml PBS between the days 16 and 26
after inoculation of the tumor cells. All experiments were
performed three times. The animals were controlled daily until
they were sacrificed.
Optical imaging
For optical imaging of xenograft tumors, animals were
anesthetized by i.p. injection of 10 ml/g anesthesia solution (10%
Ketavet/Pharmacia & Upjohn, Erlangen, Germany, 8% Rom-
pun, Bayer, Leverkusen, Germany and 82% NaCl 0.9%).
Simultaneously, 300 ml D-Luciferin (15 mg/ml, Synchem, Ger-
many) were injected i.p. Imaging was performed 10 minutes p.i.
using a cooled CCD-camera (Hamamatsu, Herrsching, Germany).
Macroscopic reduction of cell clones in vivo
Two SCID-mice with intraperitoneal MDA-MB-435 xenografts
were treated with 661.85 MBq
213Bi-DTPA-[F3]2 between the
days 4 and 14 after inoculation of tumor cells as described above,
two others with66100 ml PBS. 50 days after injection of xenografts,
mice were sacrificed and the small intestine and the colon were
preparated for macroscopic examination of tumor spread.
Statistical Analysis
Statistical analysis of cell-survival-studies was performed using
the student t-test for paired values and with t-test according to
Lord and Moore for unpaired values. Kaplan-Meier curves were
analyzed by a Log Rank Test.
Results
Binding and internalization of
213Bi-DTPA-[F3]2
To couple F3 to the a-particle emitting isotope
213Bi, DTPA-
[F3]2 was synthesized which is a F3-dimer linked to DTPA. The
chelator DTPA effectively binds metal ions such as
213Bi. It was
reported recently by Porkka et al. reported [14] that F3 is
internalized into the nucleus of tumor cells and tumor endothelial
cells in vitro and in vivo. We therefore asked whether also
213Bi-
DTPA-[F3]2 would also be internalized into the nucleus of tumor
cells. To address this question we incubated MDA-MB-435 tumor
cells with
213Bi-DTPA-[F3]2 in vitro and after the time periods
indicated in figure 1, separated the cytoplasm and the nuclei of the
tumor cells and measured the radioactivity concentration present
in each fraction. As shown in figure 1 activities measured per
volume were up to 200fold higher in the nuclei and up to 30fold
higher in the cytoplasm compared to the cell culture supernatant
containing unbound
213Bi-DTPA-[F3]2, indicating that
213Bi-
DTPA-[F3]2 accumulates in tumor cells. Peak activities were
found as early as 5 minutes after initiation of exposure, but
elevated levels were found for at least 90 minutes, i.e. two half-lifes
of
213Bi. To test whether the uptake of
213Bi-DTPA-[F3]2 into
tumor cells is specific we performed blocking experiments using
DTPA-[F3]2 not labelled with
213Bi. Cells were grown on glass
cover slips and incubated with
213Bi-DTPA-[F3]26DTPA-[F3]2
for 5 minutes. After extensive washing the cover-slips were
analyzed by a micro-imager to visualize radioactivity. The inset
to figure 1 shows that binding of
213Bi-DTPA-[F3]2 to tumor cells
can be blocked by an excess of unlabelled peptide consistent with
specificity of binding.
Anti-tumor activity of
213Bi-DTPA-[F3]2 in vitro
As F3 was shown to be internalized into the nucleus of tumor
cells and therefore may be an appropriate carrier for a-particle
emitting isotopes, we investigated the potential of
213Bi-DTPA-
[F3]2 to effectively reduce the number of cells in a tumor cell
population. For this purpose we performed colony formation
assays (Figure 2). We found that
213Bi-DTPA-[F3]2 significantly
reduced the number of clones resulting from MDA-MB-435 cells
in a dose dependent manner (p,0.01). Furthermore,
213Bi-DTPA-
[F3]2 was found to be effective on a variety of tumor cells from
Delivery of Alpha-Emitters
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including pancreas carcinoma (MIAPACA), colon carcinoma
(CMT 93) and ovarian cancer (OvCAR3). Table 1 indicates the
ID50 values for these cell lines, i.e. the
213Bi-activity concentration
reducing the number of malignant clones by 50% compared to a
control. We also tested the cytotoxic effect of
213Bi-DTPA-[F3]2 by
staining dead cells. The inset to figure 3 indicates that
213Bi-
DTPA-[F3]2 induced cell death in a dose dependent manner. In
contrast, free
213Bi is less active. These findings show that
213Bi-
DTPA-[F3]2 has a specific anti-tumor activity in vitro. DTPA-[F3]2
not labelled with
213Bi did not block cell growth and did not
induce cell death (10 pg/ml to 100 ng/ml; data not shown).
Biodistribution of
213Bi-DTPA-[F3]2
We next asked whether
213Bi-DTPA-[F3]2 does accumulate in
tumor cells in vivo.
213Bi-DTPA-[F3]2 (3.7 MBq) was injected i.p.
into mice with intra-peritoneal xenograft tumors. After one half
life of
213Bi, mice were sacrificed, the tumors and the organs were
surgically removed and the radioactivity present in each organ, the
tumors and the blood was measured with a c-counter. Up to 32%
of the injected dose/g was found in the tumors. No significant
accumulation of
213Bi-DTPA-[F3]2 could be detected in all other
organs except for the kidneys. The renal accumulation is most
likely due to excretion of the radio-labeled peptide. The tumor/
blood ratio was 17.6:1 (Figure 3a). The tumor/intestine ration was
10.37:1. To further demonstrate accumulation of F3 in intraper-
itoneal tumors we performed PET studies. Mice bearing
intraperitoneal xenograft tumors were imaged 2 hours after
injection with
68Ga-DOTA-F3 using a dedicated small animal
PET machine. The inset to figure 3a depicts a representative PET-
image.
213Bi-DTPA-[F3]2 may therefore be an appropriate tool for
the therapy of peritoneal carcinomatosis.
To test in which tumor regions
213Bi-DTPA-[F3]2 accumulates
within xenograft tumors autoradiography studies were performed.
We found that
213Bi-DTPA-[F3]2-activity accumulates primarily
in the periphery of the tumor and in peri-vascular regions. In
contrast, only low amounts of
213Bi-activity were found in control
organs such as muscle (Figure 3b).
Treatment of peritoneal carcinomatosis by
213Bi-DTPA-
[F3]2 in vivo
To study anti-tumor activity of
213Bi-DTPA-[F3]2,1 0
7 MDA-
MB-435 cells expressing firefly luciferase were injected i.p. into
SCID-mice. In one set of experiments (tumor prevention study) we
tested whether
213Bi-DTPA-[F3]2 treatment blocks the growth of
small intra-peritoneal tumors. Between the days 4–14 after
inoculation of tumor cells 661.85 MBq of
213Bi-DTPA-[F3]2
were injected for treatment every other day. In control groups we
injected either 661.85 MBq of
213Bi-DTPA or 66100 ml PBS.
The injection schedule is depicted in figure 4a. Optical imaging
revealed that treatment of mice with
213Bi-DTPA-[F3]2 inhibited
tumor growth (Figure 4b). The survival time of mice in each group
Figure 1. Internalization of
213Bi-DTPA-[F3]2 into MDA-MB-435 tumor cells. The radioactivity concentration present in the cytoplasm and
the nuclei of cells incubated with 3.7 kBq/ml
213Bi-DTPA-[F3]2 for the indicated time periods was measured and compared to the radioactivity
concentration in the supernatant. The bars represent the radioactivity in the nuclei (black, p,0.01, *=p,0.02) or the cytoplasm (white, p,0.01)
compared to the supernatant. Values6SEM are shown. The inset shows binding of
213Bi-DTPA-[F3]2 to tumor cells grown on glass cover slips in
presence or absence of unlabelled DTPA-[F3]2, visualized by a micro imager.
doi:10.1371/journal.pone.0005715.g001
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prevention study treated was 51 and 53 days for mice treated with
213Bi-DTPA or PBS, whereas mice treated with
213Bi-DTPA-[F3]2
lived an average of 93.5 days, indicating a significant (80%;
p,0.001) increase of survival by
213Bi-DTPA-[F3]2 (Figure 4c).
We also surgically removed the intraperitoneal tumors in mice
treated with
213Bi-DTPA-[F3]2 or treated with PBS for macro-
scopic visual examination. As shown in figure 4d 50 days after
injection of tumor cells mice treated with
213Bi-DTPA-[F3]2
exhibited only a small number of tumor nodules whereas mice
mock-treated with PBS showed multiple tumors within the
peritoneum.
In a tumor reduction study we tested whether
213Bi-DTPA-
[F3]2 is also effective in the treatment of large intraperitoneal
tumors. Between the days 16 and 26 after inoculation of tumor
cells we i.p. injected 661.85 MBq
213Bi-DTPA-[F3]2,
661.85 MBq
213Bi-DTPA or 66100 ml PBS were (Figure 5a).
Again, optical imaging confirmed lower tumor loads after
treatment with
213Bi-DTPA-[F3]2 (Figure 5b). In this study the
mean survival of mice was 57 days in the PBS group, 48 days in
the group treated with
213Bi-DTPA and 78 days in the
213Bi-
DTPA-[F3]2-group, i.e. there was a trend of increased survival
which was statistically significant (p=0.04; Figure 5c).
Toxicity of
213Bi-DTPA-[F3]2 -treatment
Our biodistribution study showed that
213Bi-DTPA-[F3]2 after
i. p. injection accumulates in tumors and is excreted via the
kidneys. Therefore, primarily renal toxic side effects are to be
expected. The serum creatinine level is a highly specific marker of
renal function. The serum concentration of creatinine was
determined in all tumor bearing mice when they were sacrificed
after therapy. We did not observe any significant elevation of the
serum creatinine level after treatment with
213Bi-DTPA-[F3]2
(data not shown) at time of sacrifice.
Discussion
a-particle emitting isotopes such as
213Bi are promising tools for
cancer therapy. Due to the high toxicity of a-particles targeted
delivery into tumor cells is a prerequisite of their application in
Figure 2. Anti-tumor-activity of
213Bi-DTPA-[F3]2 in vitro. MDA-MB-435 tumor cells were incubated for 12 h with different activities of
213Bi-
DTPA-[F3]2 as indicated. The number of malignant cell clones growing in soft agar was determined after 14 days and compared to untreated cells.
Values6SEM are shown (n=6, p,0.01). The inset shows that cell death is induced by
213Bi-DTPA-[F3]2, as detected by Trypan blue staining of cells
(solid line).
213Bi induced significantly lower numbers of dead cells (dashed line) (n=3, *=p,0.01).
doi:10.1371/journal.pone.0005715.g002
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not in other organs are required. Ideally, the unbound molecules
should be rapidly excreted and the carrier should mediate an
internalization of the nuclide into the nucleus of tumor cells to
enhance the DNA-damage and to reduce the cytotoxic effects on
neighbouring cells within normal tissue. We generated conjugates
of the vascular tumor homing peptide F3 and the metal chelator
DTPA which effectively chelate
213Bi.
213Bi-DTPA-[F3]2 is
internalized into the cytoplasm and the nucleus of tumor cells,
as already reported for FITC-labelled F3-peptide [10]. The peak
activity of
213Bi-DTPA-[F3]2 within the nucleus was found
approximately 5 minutes after application but significantly
elevated levels were found for at least 90 minutes. As the half-
life of
213Bi is approximately 46 minutes, a considerable amount of
the isotope will decay in the nucleus, damaging the DNA of cancer
cells but not the surrounding tissue. Therefore,
213Bi-DTPA-[F3]2
induces cell death in tumor cells and effectively reduces the
number of malignant tumor cell clones in vitro. This was
demonstrated for of a variety of tumor cell lines from different
types of carcinoma including pancreatic-, colon- and ovary
carcinoma as well as breast cancer. Within the tumors
213Bi-
DTPA-[F3]2 is primarily located in the tumor periphery and in the
peri-vascular region. In contrast, only small amounts of radioac-
tivity were detected in non-target organs except for the kidneys
were
213Bi-DTPA-[F3]2 is present presumably due to secretion of
the peptide. In previous studies by Porkka et al. [14] FITC-F3 was
also found in single cells in the intestine and in the skin, whereas in
our study no relevant activities were found in these tissues. This
Figure 3. (a) Biodistribution of
213Bi-DTPA-[F3]2. 3.7 MBq of
213Bi-DTPA-[F3]2 were injected i.p. into mice bearing intra-peritoneal MDA-MB-435
xenograft tumors. After 45 minutes the
213Bi-DTPA-[F3]2 activity present in individual organs, the tumors and the blood was measured. Values
represent the percentage of the injected dose/g tissue (%ID/g)6SEM. The inset depicts a mouse with peritoneal carcinomatosis imaged with
68Ga-
DOTA-F3-PET. The asterics (*) indicates the location of the kidneys. b) Autoradiography studies were performed using histological sections of MDA-
MB-435 xenograft tumors or muscle tissue.
213Bi-DTPA-[F3]2 was found in tumors 45 minutes after i. p. injection.
213Bi-DTPA-[F3]2 was found in the
periphery of the tumor as well as in spots within the tumor tissue. H&E-staining and microscopy (100fold magnification) of the sections revealed that
the intra-tumoral accumulation of
213Bi-DTPA-[F3]2 occurs in the perivascular region. The H&E-stained picture represents the area within the white
box in the autoradiography picture. Negligible activities were found in autoradiography pictures of control organs such as muscle.
doi:10.1371/journal.pone.0005715.g003
Table 1. The table shows the ID50 values of
213Bi-DTPA-[F3]2,
i.e. the activity concentration reducing the number of clones
in a colony formation assay by 50% in different cell lines
(EMT6, CMT93, MIAPACA, OVCAR3, MDA-MD-435).
Cell Line Organ
213Bi-DTPA-[F3]2 ID50 (kBq/ml)
EMT6 Breast Cancer 23.9
MIAPACA Pancreas Carcinoma 32.3
CMT93 Colon Carcinoma 99.5
OVCAR3 Ovarian Carcinoma 94.0
MDA-MB-435 Breast Cancer 119
doi:10.1371/journal.pone.0005715.t001
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organs which masks the quantitatively low yet potentially specific
uptake in a small group of cells.
Application of
213Bi-DTPA-[F3]2 by i.p. injection into animals
with peritoneal carcinomatosis of MDA-MB-435 cells blocks
tumor growth and increases the survival of the animals. Moreover,
213Bi-DTPA-[F3]2 not only blocks the growth of small tumor
nodules but also reduces the growth of large intraperitoneal
tumors.
The internalization of
213Bi-DTPA-[F3]2 into the nucleus seems
to be necessary for its anti tumor activity as
213Bi-DTPA had no
relevant effectinvivo and waslessactiveinvitro.AsF3isa fragment
of the HMGN2 protein which is known to be associated with
chromatin in a cell cycle dependent manner F3 transports
213Bi
potentially into close proximity of DNA enhancing the effect of the
a-particles [23]. Taken together, these findings indicate that
213Bi-
DTPA-[F3]2 is a promising new tool in the treatment of peritoneal
carcinomatosis which may be helpful in many patients. As for
example a high number of patients with ovarian cancer presents
with peritoneal carcinomatosis at the time of diagnosis,
213Bi-
DTPA-[F3]2 may be useful in treating small tumor nodules which
are not visible by clinical inspection and improve the diagnosis of
these patients by preventing tumor growth.
213Bi-DTPA-[F3]2 may
also be useful for palliative treatment in patients with advanced
peritoneal carcinomatosis spread throughout the whole abdomen as
we found a trend of longer survival of animals treated with
213Bi-
DTPA-[F3]2. As advanced peritoneal carcinomatosis is poorly
responsive to chemotherapy and frequently leads to complications
such as ascites
213Bi-DTPA-[F3]2 may also help to alleviate such
complications. We found that
213Bi-DTPA-[F3]2 blocks the clone
formation of tumor cells from many tumor types causing peritoneal
carcinomatosis, it may be helpful to reduce tumor growth and to
reduce complications such as ascites. It has been shown that F3
binds to many tumor entities including breast and prostate cancer
suggesting that F3-directed therapy may be widely applicable.
Though a-particles are highly cytotoxic, we did not observe
severe side effects in animals i. p. treated with
213Bi-DTPA-[F3]2
over a three month observation period. We can not exclude the
possibility that pathological changes might become apparent at later
time points. As biodistribution studies revealed that
213Bi-DTPA-
[F3]2 is excreted via the kidneys but does not accumulate in other
organs, primarily renal side effects are to be expected. Assessment of
renal function in mice treated with
213Bi-DTPA-[F3]2 did not show
any pathological changes in creatinine levels. As it has been shown
that the internalization of F3 into the nucleus is correlated to cell
proliferation, in kidney cells nuclear internalization of F3 may be
low due to a low proliferation rate resulting in a low nephro-toxicity
of
213Bi-DTPA-[F3]2 [14,15].
It has been shown that a-emitting isotopes such as
225Ac and
213Bi
coupled to cancer-specific antibodies are effective in the treatment of
Figure 4. Tumor prevention study. (a) The scheme depicts the time points when
213Bi-DTPA-[F3]2,
213Bi-DTPA or PBS were injected and the time
points when optical imaging was performed. (b) Assessment of the tumor growth of MDA-MB-435luc2 xenograft tumors by optical imaging in a
mouse treated with
213Bi-DTPA-[F3]2 or in a control mouse treated with PBS. (c) Kaplan-Meier analysis of the survival of mice with intraperitoneal
tumors treated with
213Bi-DTPA-[F3]2 (red),
213Bi-DTPA (green) or PBS (black). (d) Macroscopic picture of small intestine and colon of tumor bearing
mice treated like those of the tumor prevention study with
213Bi-DTPA-[F3]2 and PBS (control) 50 days after inoculation with MDA-MB-435 cells i.p.
doi:10.1371/journal.pone.0005715.g004
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models [24,25,26,27,28]. Here we report for the first time on a
tumor-homing-peptide as a carrier for the a-particle emitting isotope
213Bi. Compared to antibodies peptides may have some advantages
For example, an advantage of peptides is the rapid renal excretion
within hours. In contrast antibodies show circulation times of up to a
week. Therefore radioactively labeled antibodies not bound to their
target molecules on tumor cells will lead to higher radiation exposure
of the reminder body compared to radioactive labeled peptides, when
labeled to a-emitterswith long halflifes such as
225Ac. As we reported
recently that the somatostatin receptor binding peptide DOTATOC
coupled to
225Ac is more effective in the therapy of neuroendocrine
tumors than DOTATOC coupled to ß-particle emitting isotopes [9].
Therefore, we propose that specific tumor-homing-peptides such as
F3 will emerge as carriers for a-particle emitting isotopes in the
future.
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